用长寿改善和公平证据研究数据分析服用抗血栓治疗的患者抽取后出血的分析
Junya Nakamura1,2, Kiyomasa Nakatsuka2, Kazuaki Uchida2,3
1Department of Dentistry and Oral Surgery, National Center for Geriatrics and Gerontology, Aichi, Japan.
Gerodontology
|July 20, 2023
概括
提取后出血在接受抗凝药或双抗血栓治疗的患者中更为频繁. 仔细的准备对于这些接受牙拔牙的人来说至关重要,以最大限度地降低出血风险.
科学领域:
- 在口腔外科手术.
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 之前对接受抗血栓治疗的患者抽取后出血的研究样本大小小小.
- 抗血栓治疗通常被处方,需要研究其对牙科手术的影响.
研究的目的:
- 使用大规模数据库,分析牙提取后患者的牙抽取后出血.
- 调查各种抗血栓治疗与提取后出血风险之间的关联.
主要方法:
- 一项大型队列研究 (n=107,767) 使用了从2014年10月到2019年3月的索赔数据.
- 抗血栓治疗被分为六组:没有,单抗血小板,双抗血小板,直接口服抗凝剂,华法林和联合疗法.
- 采用多重逻辑回归分析来评估抗血栓治疗与抽取后出血之间的关联,根据年龄,性别和并发症进行调整.
主要成果:
- 13.3%的患者接受了抗血栓治疗,其中0.4%的患者经历了提取后出血.
- 与其他组相比,在没有接受抗血栓治疗或单次抗血小板治疗的患者中,抽取后出血的发生率明显较低.
- 在高危人群中,抽取后出血的几率比率从2.00到9.02不等.
结论:
- 接受抗凝药或双抗血栓治疗的患者表现出更高的抽取后出血频率.
- 在拔牙之前,这些疗法对患者的积极管理和仔细准备至关重要.
- 这项研究强调了在服用抗血栓药物患者的牙科手术中风险分层的重要性.
相关概念视频
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Anticoagulant Drugs: Low-Molecular-Weight Heparins
757
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
757
Venous Thrombosis IV: Nursing Management
14
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
14
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Disorders of Hemostasis
998
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
998
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
563
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
563


